Cargando…

Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats

Reproductive dysfunctions (RDs) characterized by impairment in testicular parameters, and metabolic disorders such as insulin resistance and type 2 diabetes mellitus (T2DM) are on the rise among human immunodeficiency virus (HIV) patients under tenofovir disoproxil fumarate (TDF) and highly active a...

Descripción completa

Detalles Bibliográficos
Autores principales: Olojede, Samuel Oluwaseun, Lawal, Sodiq Kolawole, Faborode, Oluwaseun Samuel, Dare, Ayobami, Aladeyelu, Okikioluwa Stephen, Moodley, Roshila, Rennie, Carmen Olivia, Naidu, Edwin Coleridge, Azu, Onyemaechi Okpara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187647/
https://www.ncbi.nlm.nih.gov/pubmed/35688844
http://dx.doi.org/10.1038/s41598-022-13321-y
_version_ 1784725210304348160
author Olojede, Samuel Oluwaseun
Lawal, Sodiq Kolawole
Faborode, Oluwaseun Samuel
Dare, Ayobami
Aladeyelu, Okikioluwa Stephen
Moodley, Roshila
Rennie, Carmen Olivia
Naidu, Edwin Coleridge
Azu, Onyemaechi Okpara
author_facet Olojede, Samuel Oluwaseun
Lawal, Sodiq Kolawole
Faborode, Oluwaseun Samuel
Dare, Ayobami
Aladeyelu, Okikioluwa Stephen
Moodley, Roshila
Rennie, Carmen Olivia
Naidu, Edwin Coleridge
Azu, Onyemaechi Okpara
author_sort Olojede, Samuel Oluwaseun
collection PubMed
description Reproductive dysfunctions (RDs) characterized by impairment in testicular parameters, and metabolic disorders such as insulin resistance and type 2 diabetes mellitus (T2DM) are on the rise among human immunodeficiency virus (HIV) patients under tenofovir disoproxil fumarate (TDF) and highly active antiretroviral therapy (HAART). These adverse effects require a nanoparticle delivery system to circumvent biological barriers and ensure adequate ARVDs to viral reservoir sites like testis. This study aimed to investigate the effect of TDF-loaded silver nanoparticles (AgNPs), TDF-AgNPs on sperm quality, hormonal profile, insulin-like growth factor 1 (IGF-1), and testicular ultrastructure in diabetic rats, a result of which could cater for the neglected reproductive and metabolic dysfunctions in HIV therapeutic modality. Thirty-six adult Sprague–Dawley rats were assigned to diabetic and non-diabetic (n = 18). T2DM was induced by fructose-streptozotocin (Frt-STZ) rat model. Subsequently, the rats in both groups were subdivided into three groups each (n = 6) and administered distilled water, TDF, and TDF-AgNP. In this study, administration of TDF-AgNP to diabetic rats significantly reduced (p < 0.05) blood glucose level (268.7 ± 10.8 mg/dL) from 429 ± 16.9 mg/dL in diabetic control and prevented a drastic reduction in sperm count and viability. More so, TDF-AgNP significantly increased (p < 0.05) Gonadotropin-Releasing Hormone (1114.3 ± 112.6 µg), Follicle Stimulating Hormone (13.2 ± 1.5 IU/L), Luteinizing Hormone (140.7 ± 15.2 IU/L), testosterone (0.2 ± 0.02 ng/L), and IGF-1 (1564.0 ± 81.6 ng/mL) compared to their respective diabetic controls (383.4 ± 63.3, 6.1 ± 1.2, 76.1 ± 9.1, 0.1 ± 0.01, 769.4 ± 83.7). Also, TDF-AgNP treated diabetic rats presented an improved testicular architecture marked with the thickened basement membrane, degenerated Sertoli cells, spermatogenic cells, and axoneme. This study has demonstrated that administration of TDF-AgNPs restored the function of hypothalamic-pituitary–gonadal axis, normalized the hormonal profile, enhanced testicular function and structure to alleviate reproductive dysfunctions in diabetic rats. This is the first study to conjugate TDF with AgNPs and examined its effects on reproductive indices, local gonadal factor and testicular ultrastructure in male diabetic rats with the potential to cater for neglected reproductive dysfunction in HIV therapeutic modality.
format Online
Article
Text
id pubmed-9187647
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91876472022-06-12 Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats Olojede, Samuel Oluwaseun Lawal, Sodiq Kolawole Faborode, Oluwaseun Samuel Dare, Ayobami Aladeyelu, Okikioluwa Stephen Moodley, Roshila Rennie, Carmen Olivia Naidu, Edwin Coleridge Azu, Onyemaechi Okpara Sci Rep Article Reproductive dysfunctions (RDs) characterized by impairment in testicular parameters, and metabolic disorders such as insulin resistance and type 2 diabetes mellitus (T2DM) are on the rise among human immunodeficiency virus (HIV) patients under tenofovir disoproxil fumarate (TDF) and highly active antiretroviral therapy (HAART). These adverse effects require a nanoparticle delivery system to circumvent biological barriers and ensure adequate ARVDs to viral reservoir sites like testis. This study aimed to investigate the effect of TDF-loaded silver nanoparticles (AgNPs), TDF-AgNPs on sperm quality, hormonal profile, insulin-like growth factor 1 (IGF-1), and testicular ultrastructure in diabetic rats, a result of which could cater for the neglected reproductive and metabolic dysfunctions in HIV therapeutic modality. Thirty-six adult Sprague–Dawley rats were assigned to diabetic and non-diabetic (n = 18). T2DM was induced by fructose-streptozotocin (Frt-STZ) rat model. Subsequently, the rats in both groups were subdivided into three groups each (n = 6) and administered distilled water, TDF, and TDF-AgNP. In this study, administration of TDF-AgNP to diabetic rats significantly reduced (p < 0.05) blood glucose level (268.7 ± 10.8 mg/dL) from 429 ± 16.9 mg/dL in diabetic control and prevented a drastic reduction in sperm count and viability. More so, TDF-AgNP significantly increased (p < 0.05) Gonadotropin-Releasing Hormone (1114.3 ± 112.6 µg), Follicle Stimulating Hormone (13.2 ± 1.5 IU/L), Luteinizing Hormone (140.7 ± 15.2 IU/L), testosterone (0.2 ± 0.02 ng/L), and IGF-1 (1564.0 ± 81.6 ng/mL) compared to their respective diabetic controls (383.4 ± 63.3, 6.1 ± 1.2, 76.1 ± 9.1, 0.1 ± 0.01, 769.4 ± 83.7). Also, TDF-AgNP treated diabetic rats presented an improved testicular architecture marked with the thickened basement membrane, degenerated Sertoli cells, spermatogenic cells, and axoneme. This study has demonstrated that administration of TDF-AgNPs restored the function of hypothalamic-pituitary–gonadal axis, normalized the hormonal profile, enhanced testicular function and structure to alleviate reproductive dysfunctions in diabetic rats. This is the first study to conjugate TDF with AgNPs and examined its effects on reproductive indices, local gonadal factor and testicular ultrastructure in male diabetic rats with the potential to cater for neglected reproductive dysfunction in HIV therapeutic modality. Nature Publishing Group UK 2022-06-10 /pmc/articles/PMC9187647/ /pubmed/35688844 http://dx.doi.org/10.1038/s41598-022-13321-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Olojede, Samuel Oluwaseun
Lawal, Sodiq Kolawole
Faborode, Oluwaseun Samuel
Dare, Ayobami
Aladeyelu, Okikioluwa Stephen
Moodley, Roshila
Rennie, Carmen Olivia
Naidu, Edwin Coleridge
Azu, Onyemaechi Okpara
Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats
title Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats
title_full Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats
title_fullStr Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats
title_full_unstemmed Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats
title_short Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats
title_sort testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187647/
https://www.ncbi.nlm.nih.gov/pubmed/35688844
http://dx.doi.org/10.1038/s41598-022-13321-y
work_keys_str_mv AT olojedesamueloluwaseun testicularultrastructureandhormonalchangesfollowingadministrationoftenofovirdisoproxilfumarateloadedsilvernanoparticleintype2diabeticrats
AT lawalsodiqkolawole testicularultrastructureandhormonalchangesfollowingadministrationoftenofovirdisoproxilfumarateloadedsilvernanoparticleintype2diabeticrats
AT faborodeoluwaseunsamuel testicularultrastructureandhormonalchangesfollowingadministrationoftenofovirdisoproxilfumarateloadedsilvernanoparticleintype2diabeticrats
AT dareayobami testicularultrastructureandhormonalchangesfollowingadministrationoftenofovirdisoproxilfumarateloadedsilvernanoparticleintype2diabeticrats
AT aladeyeluokikioluwastephen testicularultrastructureandhormonalchangesfollowingadministrationoftenofovirdisoproxilfumarateloadedsilvernanoparticleintype2diabeticrats
AT moodleyroshila testicularultrastructureandhormonalchangesfollowingadministrationoftenofovirdisoproxilfumarateloadedsilvernanoparticleintype2diabeticrats
AT renniecarmenolivia testicularultrastructureandhormonalchangesfollowingadministrationoftenofovirdisoproxilfumarateloadedsilvernanoparticleintype2diabeticrats
AT naiduedwincoleridge testicularultrastructureandhormonalchangesfollowingadministrationoftenofovirdisoproxilfumarateloadedsilvernanoparticleintype2diabeticrats
AT azuonyemaechiokpara testicularultrastructureandhormonalchangesfollowingadministrationoftenofovirdisoproxilfumarateloadedsilvernanoparticleintype2diabeticrats